- Kingdom of Saudi Arabia pharmaceutical leader Avalon Pharma launches innovative herbal cough syrup approved for patients two years and older in its latest effort to expand its growing product line
Riyadh, KSA, 22 August 2024: Avalon Pharma, one of the fastest growing home-grown pharmaceutical companies in the Kingdom of Saudi Arabia, introduced an innovative herbal cough syrup to the market, suitable for treating both adult patients and young children two years and older. This product is part of Avalon Pharma’s broader strategy to support Saudi Arabia’s goals in localizing essential medication production, which is crucial for enhancing national health security.
Originating in the Kingdom of Saudi Arabia, Avalon Pharma has a storied 25-year history, marked by its pursuit of excellence in the health, beauty, and prescription medicine sectors. With consistent growth and a focus on strategic expansion, including the registration of a new production line, the company is working to reinforce its position in the market.
Mohamed Maher Alghannam, Managing Director & CEO of Avalon Pharma, said: “As we continue to develop our wide range of products, we are thrilled to introduce the herbal cough syrup. A great deal of research went into its launch, demonstrating Avalon Pharma’s commitment to expanding our product range to better meet the needs of the market. Our plans to continue developing pediatric products will remain a key focus and prove vital in the years to come.”
Avalon Pharma is set to broaden its product range further, a move signaled by the introduction of innovative pediatric medications. The launch of the cough syrup will be followed by an additional line of effervescent cough syrup tablets exclusively for adults. Avalon Pharma’s product expansion efforts also encompass pain management medications as well as a new selection of pediatric pharmaceuticals.
Furthering its commitment to the Kingdom’s strategic initiatives, Avalon Pharma is also set to launch its fourth state-of-the-art manufacturing facility in Saudi Arabia. These efforts highlight the company’s involvement in supporting the Kingdom’s healthcare sector and pharmaceutical manufacturing.
